Clinical Trial for Early Dementia and Mild Cognitive Impairment
The Boston University Alzheimer’s Disease Center is recruiting subjects for a clinical research study, A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomized Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease.
The study drug is called BAN2401, a humanized monoclonal antibody that targets amyloid beta.
You may be eligible for the study if you:
- Are 50 to 90 years old
- Have a diagnosis of Mild Cognitive impairment (MCI) or
- Have a diagnosis of very early Alzheimer’s disease
- Have a caregiver who can accompany you for some of the study visits
What happens during the study?
You will complete a screening visit to determine if you are eligible for the study.
As part of the screening procedures, you will have a MRI and a PET scan using Amyvid, an approved compound to determine presence or absence of amyloid deposits in the brain.
If you are eligible, you will be enrolled in the study and receive either study drug BAN2401 or placebo intravenously every two weeks for a period of 18 months.
You will have tests of memory to assess the effects of the study drug, along with MRIs, physical examinations and EKGs to assess for drug safety.
Where is the study taking place?
Boston University Medical Center
How do I find out more about the study?
Please call Jane Mwicigi at 617-638-5670 or toll free at 888-458-2823.
Robert A. Stern, PhD – Principal Investigator
Wendy Qiu, MD, PhD – Study Physician
Jane Mwicigi, MPH – Study Coordinator